Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Bio-Path Holdings, Inc. (BPTH)
USD0.04
-0.01 (-18.03%)
US OTC Healthcare Biotechnology
Address
4710 Bellaire Boulevard 77401
Bellaire, TX, US
Bellaire, TX, US
CEO
Vikram Paul Grover
Website
biopathholdings.com
IPO
2008-03-04
CIK 1133818 ISIN US09057N4097
Description
Bio-Path Holdings, Inc. is a U.S.-based pharmaceutical company focused on developing RNAi nanoparticle drugs for oncology, with programs spanning both clinical and preclinical stages. Its innovative product development is centered around the DNAbilize platform, a drug delivery and antisense technology that employs a P-ethoxy modified deoxyribonucleic acid (DNA) backbone. This modification is specifically engineered to shield the DNA from premature degradation. The company's lead drug candidate, prexigebersen, is presently in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. Additionally, Bio-Path is advancing Liposomal Bcl-2 for refractory/relapsed lymphoma and chronic lymphocytic leukemia. Another promising asset, Liposomal STAT3, is in preclinical development, targeting pancreatic cancer, non-small cell lung cancer, and AML. Furthermore, prexigebersen-A is under development for various solid tumors. Bio-Path Holdings, Inc., founded in 2007, is headquartered in Bellaire, Texas.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.04
-0.01 (-18.03%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
32.6K
Beta
-0.41
Float Shares
9.34M
Free Float %
100.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +7.69% | -26.88% | -48.85% | -60.95% | -63.56% | -55.67% | -86.00% | -99.92% | -99.98% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (5 ratings, all time)
Buy
Price Targets & DCF
Current price
0.04
Ratings Trend (MoM)
100% Bullish
| Rating | 2025-09 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-304.49
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+73.3% ★ Q1'26: +92.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+229.3% Q1'26: +32.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.06× Q1'26: -0.43× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 2.50M (-100.0%)
|
—
est: 20.00M (-100.0%)
|
—
est: 30.00M (-100.0%)
|
—
est: 81.44M (-100.0%)
|
—
|
—
est: 21.61M (-100.0%)
|
40.06M
40.06M – 40.06M
+85.4% YoY
|
39.84M
39.84M – 39.84M
-0.5% YoY
|
48.33M
48.33M – 48.33M
+21.3% YoY
|
73.41M
73.41M – 73.41M
+51.9% YoY
|
| EBITDA |
-5.27M
|
-8.16M
|
-8.37M
|
-10.73M
|
-9.74M
|
-8.24M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-5.47M
|
-8.58M
|
-8.60M
|
-10.91M
|
-9.89M
|
-8.33M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-5.47M
est: -480.20M (+98.9%)
|
-8.58M
est: -864.36M (+99.0%)
|
-8.51M
est: -152.22M (+94.4%)
|
-10.86M
est: -145.98M (+92.6%)
|
-9.89M
est: -7.61M (-30.0%)
|
-8.67M
est: -12.57M (+31.0%)
|
-11.23M
-11.23M – -11.23M
+10.7% YoY
|
-10.83M
-10.83M – -10.83M
+3.5% YoY
|
11.86M
11.86M – 11.86M
+209.5% YoY
|
16.92M
16.92M – 16.92M
+42.7% YoY
|
| SGA |
2.46M
|
3.38M
|
4.11M
|
4.33M
|
4.70M
|
1.94M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-243.61
est: -200.00 (-21.8%)
|
-287.54
est: -360.00 (+20.1%)
|
-64.02
est: -63.40 (-1.0%)
|
-56.44
est: -60.80 (+7.2%)
|
-4.12
est: -3.17 (-30.0%)
|
-1.10
est: -1.59 (+30.8%)
|
-1.42
-1.42 – -1.42
+10.7% YoY
|
-1.37
-1.37 – -1.37
+3.5% YoY
|
1.50
1.50 – 1.50
+209.5% YoY
|
2.14
2.14 – 2.14
+42.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-11.53M
OE per share TTM
-25.91
Owner's Yield
-4,691.91%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
8,678.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
21
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Hudson Bay Capital Management LP | 709.6K | 5.43% | — | 709.6K | — | — | PN | State of Delaware | 2024-02-02 | ↗ |
| 2 | Sander Gerber | 709.6K | 5.43% | — | 709.6K | — | — | IN | United States | 2024-02-02 | ↗ |
| 3 | CVI Investments, Inc. | 202.0K | 5.50% | — | 202.0K | — | 202.0K | CO | Cayman Islands | 2019-12-02 | ↗ |
| 4 | Heights Capital Management, Inc. | 202.0K | 5.50% | — | 202.0K | — | 202.0K | CO | Delaware | 2019-12-02 | ↗ |
| 5 | Armistice Capital Master Fund Ltd. | 151.5K | 3.90% | — | 151.5K | — | 151.5K | CO | Delaware | 2019-11-27 | ↗ |
| 6 | Armistice Capital, LLC | 151.5K | 3.90% | — | 151.5K | — | 151.5K | IA, OO | Delaware | 2019-11-27 | ↗ |
| 7 | Steven Boyd | 151.5K | 3.90% | — | 151.5K | — | 151.5K | HC, IN | Delaware | 2019-11-27 | ↗ |
| 8 | Inc. | 106.7K | 6.10% | — | 106.7K | — | 106.7K | CO | Texas | 2019-02-04 | ↗ |
| 9 | Kassam | 106.7K | 6.10% | — | 106.7K | — | 106.7K | IN | Texas | 2019-02-04 | ↗ |
| 10 | LLC | 106.7K | 6.10% | — | 106.7K | — | 106.7K | HC, OO | Texas | 2019-02-04 | ↗ |
| 11 | Management LP | 106.7K | 6.10% | — | 106.7K | — | 106.7K | IA, PN | Texas | 2019-02-04 | ↗ |
| 12 | Nathoo | 106.7K | 6.10% | — | 106.7K | — | 106.7K | IN | Texas | 2019-02-04 | ↗ |
| 13 | Winson | 106.7K | 6.10% | — | 106.7K | — | 106.7K | HC, IN | Texas | 2019-02-04 | ↗ |
| 14 | 5.9% (1) | 106.0K | 5.90% | 106.0K | — | 106.0K | — | OO | Delaware | 2019-03-15 | ↗ |
| 15 | Empery Asset Management, LP | 97.8K | 9.27% | — | 97.8K | — | — | PN | Delaware | 2019-01-24 | ↗ |
| 16 | Martin D. Hoe | 97.8K | 9.27% | — | 97.8K | — | — | IN | United States | 2019-01-24 | ↗ |
| 17 | Ryan M. Lane | 97.8K | 9.27% | — | 97.8K | — | — | IN | United States | 2019-01-24 | ↗ |
| 18 | 10 | 56.8K | 3.20% | 56.8K | 15.00 | 56.8K | 15.00 | IA | Delaware | 2019-03-15 | ↗ |
| 19 | Daniel B. Asher | 53.7K | 7.10% | — | 53.7K | — | 49.2K | HC, IN | United States of America | 2024-04-03 | ↗ |
| 20 | Intracoastal Capital LLC | 53.7K | 7.10% | — | 53.7K | — | 49.2K | OO | Delaware | 2024-04-03 | ↗ |
| 21 | Mitchell P. Kopin | 53.7K | 7.10% | — | 53.7K | — | 49.2K | HC, IN | United States of America | 2024-04-03 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
5
Sells
0
Shares acquired
34.5K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+34,537
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-07-30 | Sherwood Aline | Director | A-Award | A | Common Stock Option (right to buy) | 2,000 | 1.55 | 3.1K | 2,000 | — | ↗ |
| 2024-07-30 | Nielsen Peter Henry | Director / Officer | A-Award | A | Common Stock Option (right to buy) | 25,000 | 1.55 | 38.8K | 25,000 | — | ↗ |
| 2024-07-30 | MORRIS DOUGLAS P | Director | A-Award | A | Common Stock Option (right to buy) | 3,537 | 1.55 | 5.5K | 3,537 | — | ↗ |
| 2024-07-30 | Cleaver Heath | Director | A-Award | A | Common Stock Option (right to buy) | 2,000 | 1.55 | 3.1K | 2,000 | — | ↗ |
| 2024-07-30 | Aubert Paul | Director | A-Award | A | Common Stock Option (right to buy) | 2,000 | 1.55 | 3.1K | 2,000 | — | ↗ |
| 2023-05-02 | Sherwood Aline | Director | A-Award | A | Common Stock Option (right to buy) | 10,000 | 1.39 | 13.9K | 10,000 | — | ↗ |
| 2023-05-02 | Nielsen Peter Henry | Director / Officer | A-Award | A | Common Stock Option (right to buy) | 105,000 | 1.39 | 146.0K | 105,000 | — | ↗ |
| 2023-05-02 | MORRIS DOUGLAS P | Director | A-Award | A | Common Stock Option (right to buy) | 13,000 | 1.39 | 18.1K | 13,000 | — | ↗ |
| 2023-05-02 | Cleaver Heath | Director | A-Award | A | Common Stock Option (right to buy) | 10,000 | 1.39 | 13.9K | 10,000 | — | ↗ |
| 2023-05-02 | Aubert Paul | Director | A-Award | A | Common Stock Option (right to buy) | 10,000 | 1.39 | 13.9K | 10,000 | — | ↗ |
| 2022-03-31 | Sherwood Aline | Director | A-Award | A | Common Stock Option (right to buy) | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2022-03-28 | MORRIS DOUGLAS P | Director | A-Award | A | Common Stock Option (right to buy) | 11,000 | 0.00 | — | 11,000 | — | ↗ |
| 2022-03-28 | Cleaver Heath | Director | A-Award | A | Common Stock Option (right to buy) | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2022-03-28 | Aubert Paul | Director | A-Award | A | Common Stock Option (right to buy) | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2022-03-23 | Nielsen Peter Henry | Officer | A-Award | A | Common Stock Option (right to buy) | 90,000 | 0.00 | — | 90,000 | — | ↗ |
| 2021-03-31 | Nielsen Peter Henry | Officer | A-Award | A | Common Stock Option (right to buy) | 100,000 | 7.02 | 702.0K | 100,000 | — | ↗ |
| 2021-03-31 | Molsbergen Tamaro Martina | Director | A-Award | A | Common Stock Option (right to buy) | 10,000 | 7.02 | 70.2K | 10,000 | — | ↗ |
| 2021-03-31 | MORRIS DOUGLAS P | Director | A-Award | A | Common Stock Option (right to buy) | 13,000 | 7.02 | 91.3K | 13,000 | — | ↗ |
| 2021-03-31 | Cleaver Heath | Director | A-Award | A | Common Stock Option (right to buy) | 10,000 | 7.02 | 70.2K | 10,000 | — | ↗ |
| 2021-03-31 | Aubert Paul | Director | A-Award | A | Common Stock Option (right to buy) | 10,000 | 7.02 | 70.2K | 10,000 | — | ↗ |
| 2020-06-16 | Nielsen Peter Henry | Director / Officer | A-Award | A | Common Stock Option (right to buy) | 85,000 | 5.21 | 442.9K | 85,000 | — | ↗ |
| 2020-03-27 | Molsbergen Tamaro Martina | Director | A-Award | A | Common Stock Option (right to buy) | 10,000 | 5.07 | 50.7K | 10,000 | — | ↗ |
| 2020-03-27 | MORRIS DOUGLAS P | Director | A-Award | A | Common Stock Option (right to buy) | 10,000 | 5.07 | 50.7K | 10,000 | — | ↗ |
| 2020-03-27 | Cleaver Heath | Director | A-Award | A | Common Stock Option (right to buy) | 10,000 | 5.07 | 50.7K | 10,000 | — | ↗ |
| 2020-03-27 | Aubert Paul | Director | A-Award | A | Common Stock Option (right to buy) | 10,000 | 5.07 | 50.7K | 10,000 | — | ↗ |
| 2020-03-18 | Nielsen Peter Henry | Director / Officer | A-Award | A | Common Stock Option (right to buy) | 15,000 | 3.25 | 48.8K | 15,000 | — | ↗ |
| 2019-10-11 | Molsbergen Tamaro Martina | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-03-28 | Nielsen Peter Henry | Director / Officer | A-Award | A | Common Stock Option (right to buy) | 15,000 | 18.40 | 276.0K | 15,000 | — | ↗ |
| 2019-03-28 | MORRIS DOUGLAS P | Director | A-Award | A | Common Stock Option (right to buy) | 1,000 | 18.40 | 18.4K | 1,000 | — | ↗ |
| 2019-03-28 | Cleaver Heath | Director | A-Award | A | Common Stock Option (right to buy) | 1,000 | 18.40 | 18.4K | 1,000 | — | ↗ |
| 2019-03-28 | COLONNESE MARK P | Director | A-Award | A | Common Stock Option (right to buy) | 1,000 | 18.40 | 18.4K | 1,000 | — | ↗ |
| 2019-03-28 | Aubert Paul | Director | A-Award | A | Common Stock Option (right to buy) | 1,000 | 18.40 | 18.4K | 1,000 | — | ↗ |
| 2019-01-18 | ARMISTICE CAPITAL, LLC | 10% Owner | — | D | Warrant | 96,878 | 0.00 | — | 0 | — | ↗ |
| 2018-04-17 | MORRIS DOUGLAS P | Director | A-Award | A | Common Stock Option (right to buy) | 20,000 | 1.68 | 33.5K | 20,000 | — | ↗ |
| 2018-04-17 | Cleaver Heath | Director | A-Award | A | Common Stock Option (right to buy) | 20,000 | 1.68 | 33.5K | 20,000 | — | ↗ |
| 2018-04-17 | COLONNESE MARK P | Director | A-Award | A | Common Stock Option (right to buy) | 20,000 | 1.68 | 33.5K | 20,000 | — | ↗ |
| 2018-04-17 | Aubert Paul | Director | A-Award | A | Common Stock Option (right to buy) | 17,500 | 1.68 | 29.3K | 17,500 | — | ↗ |
| 2018-04-11 | Nielsen Peter Henry | Director / Officer | A-Award | A | Common Stock Option (right to buy) | 130,000 | 1.84 | 239.2K | 130,000 | — | ↗ |
| 2018-02-01 | Aubert Paul | Director | A-Award | A | Common Stock Option (right to buy) | 25,000 | 0.20 | 5.0K | 25,000 | — | ↗ |
| 2017-07-13 | COLONNESE MARK P | Director | A-Award | A | Common Stock Option (right to buy) | 25,000 | 0.38 | 9.5K | 25,000 | — | ↗ |
| 2017-05-01 | Mueller Ulrich W. | Officer | A-Award | A | Common Stock Option (right to buy) | 125,000 | 0.67 | 83.7K | 125,000 | — | ↗ |
| 2017-03-23 | SING AMY | Director | A-Award | A | Common Stock Option (right to buy) | 25,000 | 0.80 | 19.9K | 25,000 | — | ↗ |
| 2017-03-23 | Mueller Ulrich W. | Officer | A-Award | A | Common Stock Option (right to buy) | 200,000 | 0.80 | 159.0K | 200,000 | — | ↗ |
| 2017-03-23 | MORRIS DOUGLAS P | Director | A-Award | A | Common Stock Option (right to buy) | 25,000 | 0.80 | 19.9K | 25,000 | — | ↗ |
| 2017-03-23 | Garrison Michael J. | Director | A-Award | A | Common Stock Option (right to buy) | 25,000 | 0.80 | 19.9K | 25,000 | — | ↗ |
| 2017-03-23 | Cleaver Heath | Director | A-Award | A | Common Stock Option (right to buy) | 25,000 | 0.80 | 19.9K | 25,000 | — | ↗ |
| 2016-05-01 | Mueller Ulrich W. | Officer | A-Award | A | Common Stock Option (right to buy) | 125,000 | 2.31 | 288.8K | 125,000 | — | ↗ |
| 2016-04-05 | SING AMY | Director | A-Award | A | Common Stock Option (right to buy) | 25,000 | 2.75 | 68.8K | 25,000 | — | ↗ |
| 2016-04-05 | Nielsen Peter Henry | Director / Officer | A-Award | A | Common Stock Option (right to buy) | 552,005 | 2.75 | 1.52M | 552,005 | — | ↗ |
| 2016-04-05 | Mueller Ulrich W. | Officer | A-Award | A | Common Stock Option (right to buy) | 361,636 | 2.75 | 994.5K | 361,636 | — | ↗ |
| 2016-04-05 | MORRIS DOUGLAS P | Director | A-Award | A | Common Stock Option (right to buy) | 25,000 | 2.75 | 68.8K | 25,000 | — | ↗ |
| 2016-04-05 | Garrison Michael J. | Director | A-Award | A | Common Stock Option (right to buy) | 25,000 | 2.75 | 68.8K | 25,000 | — | ↗ |
| 2016-04-05 | Cleaver Heath | Director | A-Award | A | Common Stock Option (right to buy) | 25,000 | 2.75 | 68.8K | 25,000 | — | ↗ |
| 2015-07-13 | Garrison Michael J. | Director | P-Purchase | A | Common Stock | 7,343 | 1.22 | 9.0K | 160,000 | — | ↗ |
| 2015-07-09 | Garrison Michael J. | Director | P-Purchase | A | Common Stock | 8,724 | 1.17 | 10.2K | 152,657 | — | ↗ |
| 2015-07-08 | Garrison Michael J. | Director | P-Purchase | A | Common Stock | 21,015 | 1.20 | 25.2K | 143,933 | — | ↗ |
| 2015-07-07 | Garrison Michael J. | Director | P-Purchase | A | Common Stock | 38,985 | 1.18 | 46.0K | 122,918 | — | ↗ |
| 2015-07-01 | Garrison Michael J. | Director | L-Small | A | Common Stock | 600 | 1.08 | 648.00 | 83,933 | — | ↗ |
| 2015-05-01 | Mueller Ulrich W. | Officer | A-Award | A | Stock Option | 125,000 | 1.45 | 180.6K | 125,000 | — | ↗ |
| 2015-03-02 | SING AMY | Director | A-Award | A | Common Stock Option | 25,000 | 1.70 | 42.5K | 25,000 | — | ↗ |
| 2015-03-02 | MORRIS DOUGLAS P | Director | A-Award | A | Common Stock Option | 25,000 | 1.70 | 42.5K | 25,000 | — | ↗ |
| 2015-03-02 | Garrison Michael J. | Director | A-Award | A | Common Stock Option | 25,000 | 1.70 | 42.5K | 25,000 | — | ↗ |
| 2015-03-02 | Cleaver Heath | Director | A-Award | A | Common Stock Option | 25,000 | 1.70 | 42.5K | 25,000 | — | ↗ |
| 2014-11-03 | SING AMY | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-10-01 | Garrison Michael J. | Director | A-Award | A | Common Stock Option | 25,000 | 1.96 | 49.0K | 25,000 | — | ↗ |
| 2014-05-01 | Mueller Ulrich W. | Officer | A-Award | A | Stock Option | 125,000 | 2.40 | 300.0K | 125,000 | — | ↗ |
| 2014-04-25 | IVERS-READ GILLIAN C | Director | A-Award | A | Stock Option | 25,000 | 2.38 | 59.5K | 25,000 | — | ↗ |
| 2014-03-26 | Mueller Ulrich W. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-02-11 | Cleaver Heath | Director | A-Award | A | Common Stock Option | 25,000 | 4.30 | 107.5K | 25,000 | — | ↗ |
| 2013-10-01 | Garrison Michael J. | Director | A-Award | D | Common Stock Option | 25,000 | 1.95 | 48.8K | 25,000 | — | ↗ |
| 2013-08-08 | Nielsen Peter Henry | Director / Officer | A-Award | A | Incentive Stock Option | 1,500,000 | 0.46 | 690.0K | 1,500,000 | — | ↗ |
| 2013-08-08 | MORRIS DOUGLAS P | Director / Officer | A-Award | A | Incentive Stock Option | 1,000,000 | 0.46 | 460.0K | 1,000,000 | — | ↗ |
| 2013-06-12 | Garrison Michael J. | Director | P-Purchase | A | Common Stock | 340,000 | 0.30 | 102.0K | 673,334 | — | ↗ |
| 2013-04-25 | IVERS-READ GILLIAN C | Director | A-Award | A | Stock Option | 25,000 | 0.52 | 13.0K | 25,000 | — | ↗ |
| 2013-02-19 | IVERS-READ GILLIAN C | Director | A-Award | A | Stock Option | 25,000 | 0.35 | 8.8K | 25,000 | — | ↗ |
| 2012-10-01 | Garrison Michael J. | Director | A-Award | D | Common Stock Option | 25,000 | 0.39 | 9.8K | 25,000 | — | ↗ |
| 2011-06-06 | IVERS-READ GILLIAN C | Director | A-Award | A | Stock Option | 25,000 | 0.33 | 8.3K | 25,000 | — | ↗ |
| 2009-12-02 | Garrison Thomas E | Director | P-Purchase | A | common stock | 350,000 | 0.25 | 87.5K | 2,511,324 | — | ↗ |
| 2009-10-13 | Garrison Thomas E | Director | P-Purchase | A | warrant | 400,000 | 1.50 | 600.0K | 400,000 | — | ↗ |
| 2008-12-18 | Garrison Thomas E | Director | A-Award | A | option | 75,000 | 0.30 | 22.5K | 75,000 | — | ↗ |
| 2008-10-14 | Nielsen Peter Henry | Director / Officer / 10% Owner | A-Award | A | common stock option | 1,500,000 | 1.40 | 2.10M | 1,500,000 | — | ↗ |
| 2008-10-14 | MORRIS DOUGLAS P | Director / Officer | A-Award | A | common stock option | 1,000,000 | 1.40 | 1.40M | 1,000,000 | — | ↗ |
| 2008-09-10 | Nielsen Peter Henry | Director / Officer | — | D | common stock | 0 | 0.00 | — | 5,164,434 | — | ↗ |
| 2008-09-10 | MORRIS DOUGLAS P | Director / Officer | — | D | common stock | 0 | 0.00 | — | 1,629,811 | — | ↗ |
| 2008-09-10 | IVERS-READ GILLIAN C | Director | — | D | common stock options | 450,000 | 0.90 | 405.0K | 0 | — | ↗ |
| 2008-09-10 | Garrison Thomas E | Director | — | D | common stock | 0 | 0.00 | — | 1,761,324 | — | ↗ |
| 2008-09-10 | Brick & Mortar Investments LLC | 10% Owner | — | D | common stock | 0 | 0.00 | — | 5,593,084 | — | ↗ |
Executive team
Top executives
Shares Outstanding
9.34M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2023 | Peter H. Nielsen, CEO, CFO, President, Chairman, Director | 575.0K | 110.0K | — | 130.9K | — | 11.2K | 827.1K | 15.82% | ↗ |
| 2 | 2022 | Peter H. Nielsen, CEO, CFO, President, Chairman, Director | 555.0K | 150.0K | — | 288.7K | — | 17.7K | 1.01M | 28.54% | ↗ |
| 3 | 2021 | Peter H. Nielsen, CEO, CFO, President, Chairman, Director | 530.0K | 150.0K | — | 622.5K | — | 179.00 | 1.30M | 47.79% | ↗ |
| 4 | 2020 | Peter H. Nielsen, CEO, CFO, President, Chairman, Director | 510.0K | 150.0K | — | 427.3K | — | 170.00 | 1.09M | 39.29% | ↗ |
| 5 | 2019 | Peter H. Nielsen, CEO, CFO, President, Chairman, Director | 490.0K | — | — | 244.6K | — | 164.00 | 734.7K | 33.29% | ↗ |
| 6 | 2018 | Peter H. Nielsen, CEO, CFO, President, Chairman, Director | 490.0K | — | — | 181.7K | — | 216.00 | 671.9K | 27.04% | ↗ |
| 7 | 2017 | Peter H. Nielsen, CEO, CFO, President, Chairman, Director | 475.0K | 118.8K | — | — | — | 208.00 | 594.0K | 0.00% | ↗ |
| 8 | 2017 | Peter H. Nielsen, CEO, CFO, President, Chairman, Director | 475.0K | 118.8K | — | — | — | 208.00 | 594.0K | 0.00% | ↗ |
| 9 | 2017 | Ulrich W. Mueller, COO, Secretary | 243.3K | 75.4K | — | 191.8K | — | 10.0K | 520.5K | 36.85% | ↗ |
| 10 | 2016 | Peter H. Nielsen, CEO, CFO, President, Chairman, Director | 456.3K | 140.0K | — | 1.26M | — | 208.00 | 1.85M | 67.79% | ↗ |
| 11 | 2016 | Peter H. Nielsen, CEO, CFO, President, Chairman, Director | 456.3K | 140.0K | — | 1.26M | — | 208.00 | 1.85M | 67.79% | ↗ |
| 12 | 2016 | Ulrich W. Mueller, COO, Secretary | 322.5K | 69.8K | — | 1.06M | — | 14.0K | 1.47M | 72.29% | ↗ |
| 13 | 2015 | Ulrich W. Mueller, COO, Secretary | 285.0K | 42.4K | — | 161.9K | — | — | 489.3K | 33.08% | ↗ |
| 14 | 2015 | Peter H. Nielsen, CEO, CFO, President, Chairman, Director | 400.0K | 75.0K | — | — | — | — | 475.0K | 0.00% | ↗ |
| 15 | 2014 | Peter H. Nielsen, CEO, CFO, President, Chairman, Director | 400.0K | 125.0K | — | — | — | — | 525.0K | 0.00% | ↗ |
| 16 | 2014 | Peter H. Nielsen, CEO, CFO, President, Chairman, Director | 400.0K | 125.0K | — | — | — | — | 525.0K | 0.00% | ↗ |
| 17 | 2014 | Ulrich W. Mueller, COO, Secretary | 190.0K | — | — | 294.9K | — | — | 484.9K | 60.81% | ↗ |
| 18 | 2014 | Douglas P. Morris, VP Corporate Development, Director | 30.0K | 12.0K | — | — | — | 2.0K | 44.0K | 0.00% | ↗ |
| 19 | 2013 | Peter H. Nielsen, CEO, CFO, President, Chairman, Director | 250.0K | 125.0K | — | — | — | — | 1.05M | 0.00% | ↗ |
| 20 | 2013 | Peter H. Nielsen, CEO, CFO, President, Chairman, Director | 250.0K | 125.0K | — | 675.0K | — | — | 1.05M | 64.29% | ↗ |
| 21 | 2013 | Douglas P. Morris, VP Corporate Development, Director | 120.0K | 60.0K | — | — | — | — | 630.0K | 0.00% | ↗ |
| 22 | 2013 | Ulrich W. Mueller, COO, Secretary | — | — | — | — | — | — | — | — | ↗ |
| 23 | 2012 | Peter H. Nielsen, CEO, CFO, President, Chairman, Director | 250.0K | — | — | — | — | — | 250.0K | 0.00% | ↗ |
| 24 | 2012 | Douglas P. Morris, VP Corporate Development, Director | 120.0K | — | — | — | — | — | 120.0K | 0.00% | ↗ |
| 25 | 2012 | Ulrich W. Mueller, COO, Secretary | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Douglas Morris | Co-Founder, Director of Investor Relations & Secretary | 76.7K | male |
| Ana Tari Ashizawa | Senior Vice President of Research, Development & Clinical Design | — | — |
| Anthony Price | Senior Vice President of Finance, Accounting & Administration | — | male |
| Michael Hickey | Member of Scientific Advisory Board & VP of Clinical Operations | — | male |
| Vikram Paul Grover | President, Chief Executive Officer, Chief Financial Officer & Director | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BPTH
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
